UK – Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer

French pharma group Pierre Fabre’s Braftovi has been recommended for NHS use by the UK’s National Institute for Health and Care Excellence (NICE) to treat BRAF-positive colorectal cancer.

Braftovi (encorafenib) combined with has been recommended Merck KGaA’s EGFR-targeting antibody Erbitux (cetuximab) has been recommended as a second-line treatment for BRAF-positive metastatic colorectal cancer (mCRC).

The positive recommendation is based on results from the phase 3 BEACON CRC study, in which Braftovi/Erbitux significantly improved overall survival (OS) by 40% compared to Erbitux and irinotecan-based chemotherapy, with a median OS of 9.3 months and 5.9 months respectively.

The trial also demonstrated that the treatment combinations was as effective as a triple therapy which also included Mektovi (binimetinib), which meant that additional toxicity from the MEK inhibitor could be avoided without comprising patient benefit…